Document:

Updated Schedule of Parties to the Employment Agreement

 EXHIBIT 10.5(b) 
 SCHEDULE OF PARTIES TO THE EMPLOYMENT AGREEMENT 
 Each of the parties identified in the table below is party to an
employment agreement with Advanced Medical Optics, Inc. substantially in the form attached to the Advanced Medical Optics, Inc. Form 10 as Exhibit 10.6(a). Each party’s employment agreement is identical except for such party’s base salary,
position, agreement date and prior agreements, each of which is set forth in the table below. The Agreements of Messrs. Meier and Trenary were amended in October 2004 for the purpose of reflecting their new titles and adjusted salaries.

 

										
	 EMPLOYEE NAME
	  	BASE
SALARY	  	 POSITION
	  	 AGREEMENT
DATE
	  	 PRIOR AGREEMENTS

	 Aimee S. Weisner
	  	 $	215,000 	  	Corporate Vice President, General Counsel and Secretary	  	January 18, 2002	  	Retention Agreement among the Company, Allergan and the Executive dated January 18, 2002
					
	 Jane E. Rady
	  	 $	250,000 	  	Corporate Vice President, Strategy and Technology	  	April 8, 2002	  	Agreement between Allergan and Executive dated April 8, 2002
					
	 C. Russell Trenary III (*)
	  	 $	300,000 	  	Corporate Vice President and Chief Marketing Officer	  	 April 24, 2002, amended
 October 1,
2004
	  	Agreement between Allergan and Executive dated April 24, 2002
					
	 Richard A. Meier
	  	 $	375,900 	  	Executive Vice President of Operations and Finance, and Chief Financial Officer	  	 April 8, 2002, amended
 October 1,
2004
	  	Agreement between Allergan and Executive dated April 8, 2002
					
	 Douglas H. Post
	  	 $	315,000 	  	Corporate Vice President and Region President, Americas	  	December 14, 2004 (but effective only upon completion of the VISX merger)	  	Not applicable.

  

	*	Mr. Trenary’s employment agreement was further amended on November 15, 2007. The amendment is being filed as a separate exhibit and further updates this Schedule.Amendment No. 2 to Employment Agreement

 EXHIBIT 10.5(d) 
 Amendment No. 2 to 
 Employment Agreement 
 This Amendment No. 2 (this “Amendment”) is entered into this 15th day of November, 2007, by and between Advanced Medical Optics, Inc. (the “Company”), and C. Russell Trenary III (the “Executive”).

 WHEREAS, the Company and the Executive have entered into that certain Employment Agreement, dated April 24, 2002, as amended by
Amendment No. 1 on October 1, 2004 (the “Agreement”); and 
 WHEREAS, the Company and the Executive desire to amend
further the Agreement; 
 NOW, THEREFORE, the parties agree as follows: 
 1. Executive hereby consents to the change in Executive’s job responsibilities and position, effective October 15, 2007, in connection with
Executive’s appointment as Executive Vice President, Global Public Policy and Medical Education, reporting to the Company’s Chief Executive Officer, and agrees that such change does not and will not constitute Good Reason under the
Agreement 
 2. Amendment to Section 2.2. Section 2.2 of the Agreement is hereby amended by replacing the words
“Corporate Vice President and Chief Marketing Officer” with “Executive Vice President, Global Public Policy and Medical Education.” 
 3. Amendment to Section 3.1. Section 3.1 of the Agreement is hereby amended and restated in its entirety as follows: “During the Term, the Company shall pay Executive a base salary (“Base
Salary”) at an annual rate of $365,700, payable in accordance with the Company’s executive compensation practices. Such annual rate shall be reviewed by the Board or its designee at least annually and may be increased, but not decreased,
in such amounts as the Board or its designee deems appropriate in its sole discretion.” 
 4. Amendment to Section 5.1(e).
Section 5.1(e) of the Agreement is hereby amended to add the following sentence: “For purposes of clarity, a “substantial diminution or adverse modification in Executive’s overall position, responsibilities or reporting
relationship” shall have occurred if (y) Executive no longer reports to the chief executive officer, or (z) if Executive is assigned to a position other than Executive Vice President, Global Public Policy and Medical Education,
unless, for purposes of this subsection (z) only, the position adds but does not remove duties, or the position is the head of sales and/or marketing for one or more business units.” 
 5. Reaffirmation of Agreement. Except as expressly set forth herein, the Agreement is not amended, modified or affected by this Amendment, and the
Agreement and the obligations of the parties thereunder are hereby ratified and confirmed by the Company and the Executive in all respects. 

 6. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall
constitute an original but all of which shall be but one and the same agreement. 
 IN WITNESS WHEREOF, the parties hereto have executed this
Amendment as of the date first written above. 
 “Company” 
 ADVANCED MEDICAL OPTICS, INC. 
 a Delaware corporation 
 By:  /s/    JAMES V.
MAZZO                                       
      
         James V. Mazzo, Chairman, President and

         Chief Executive Officer 
  
 “Executive” 
  
 /s/    C. RUSSELL TRENARY
III                                        

 C. Russell Trenary III2008 Performance Objective

 EXHIBIT 10.8(f) 
  

	 AMO BONUS PLAN 
	 

 

 2008 PERFORMANCE OBJECTIVE 
  
  
 2008 PERFORMANCE OBJECTIVE 
 The 2008 performance objective for the Bonus Plan is 75% based on Adjusted Operating Income and 25% based on
Revenue for the full year of AMO performance. “Adjusted Operating Income” is defined as sales less cost of goods sold and all basic operating expenses of the business. “Adjusted Operating Income” excludes the impact of charges or
write-offs associated with acquisitions, reorganizations and recapitalizations, unrealized gains or losses on derivative instruments and other periodic or one-time charges. “Revenue” is defined as the total dollar payment for goods and
services that are credited to the income statement over the measurement period. 
 Each segment of the bonus is funded when AMO achieves the threshold levels
of Adjusted Operating Income and Revenue performance, respectively, as indicated below. If the Adjusted Operating Income funding trigger threshold is not met, the 75% element of the plan is not funded. If the Revenue funding trigger threshold is not
met, the 25% element of the plan is not funded. If neither funding trigger threshold is met, no bonuses will be funded. 
  
  
 FUNDING TRIGGER ELEMENTS 
  

																			
	 75% - ADJUSTED OPERATING INCOME
	 	    	 25% - REVENUE
	 
	 Performance Level
	  	 2008
Adj Op Range
Variance
to
Target
	  	Funding %
to Adj Op
Target	 	 	Plan
Funding	 	    	 Performance Level
	  	 2008
Revenue Range
Variance to
Target
	  	Funding %
to Revenue
Target	 	 	Plan
Funding	 
	 Below Threshold
	  	-33.01 mm	  	0	%	 	0.0	%	    	Below Threshold	  	-61.76 mm	  	0	%	 	0.0	%
	 Threshold
	  	-33.0 mm	  	50	%	 	37.5	%	    	Threshold	  	-61.75 mm	  	50	%	 	12.5	%
	 Tier 1
	  	-22.0 mm	  	90	%	 	67.5	%	    	Tier 1	  	-10.00 mm	  	95	%	 	23.8	%
		  	Target	  	100	%	 	75.0	%	    		  	Target	  	100	%	 	25.0	%
	 Maximum
	  	+33.0 mm	  	200	%	 	150.0	%	    	Maximum	  	+185.25 mm	  	200	%	 	50.0	%
		
	 If actual Adjusted Operating Income results fall
 between the performance levels shown above, the
 portion of bonus funding will be
prorated accordingly.
	  
  
  
	    	 If actual Revenue results fall between the Tiers shown
 above, the portion of bonus funding will be prorated
 accordingly.
	  
  
  

  

  
 BONUS POOL
FUNDING 
 At the end of the year, the Chief Executive Officer of Advanced Medical Optics, Inc. may recommend adjustments to the bonus funding levels to
the Organization, Compensation and Corporate Governance Committee (the “Committee”) after consideration of key operating results. When calculating Adjusted Operating Income and Revenue performance for purposes of this Plan, the Committee
has the discretion to include or exclude any or all of the following items: 
  

	 	•	 	 Extraordinary, unusual or non-recurring items 

  

	 	•	 	 Effects of accounting changes 

  

	 	•	 	 Effects of financing activities 

  

	 	•	 	 Expenses for restructuring or productivity initiatives 

  

	 	•	 	 Other non-operating items 

  

	 	•	 	 Spending for acquisitions 

  

	 	•	 	 Effects of divestitures 

  
  
 BONUS POOL DIFFERENTIATION BY BUSINESS UNIT/FUNCTION

 The target bonus pool is determined by performance against Adjusted Operating Income (75%) and Revenue (25%). The factors below will be
considered for allocation of SBU/function bonus pools: 
 CORPORATE STAFFS 
  

	 	•	 	 Corporate Adjusted Operating Income 

  

	 	•	 	 Corporate Revenue 

  

	 	•	 	 Strategic metrics and milestones 

 STRATEGIC
BUSINESS UNITS 
  

	 	•	 	 Business Unit Adjusted Operating Income 

  

	 	•	 	 Business Unit Revenue 

  

	 	•	 	 Strategic metrics 

 RESEARCH &
DEVELOPMENT, WORLD WIDE MANUFACTURING, GLOBAL CUSTOMER SERVICES, IT 
  

	 	•	 	 Strategic metrics and milestones 

  

  
 INDIVIDUAL
BONUS AWARD CALCULATION 
 Target bonus awards are expressed as a percentage of the participant’s year-end annualized base salary. The target
percentages for managers other than corporate officers vary by salary grade: 
  

			
	 SALARY GRADE
	 	 TARGET BONUS

	  5E*	 	  5%
	  6E*	 	10%
	7E	 	15%
	8E	 	20%
	9E	 	25%
	10E	 	30%
	11E	 	35%

 Target percentages or amounts for corporate officers are individually established by the Committee.

 A participant’s actual bonus award may vary above or below the targeted level based on the supervisor’s evaluation of his or her performance in
relation to the predetermined MBOs. Within the funded bonus pool, each participant may receive from 0% to 150% of his or her target bonus amount. 
  

	*	U.S. and Puerto Rico employees only.Form of Employee Nonqualified Stock Option Grant

 EXHIBIT 10.12(b) 
 Advanced Medical Optics, Inc. 
 NONQUALIFIED STOCK OPTION GRANT 
 TERMS AND CONDITIONS 
 As of April 2007 
 1. Definitions. Capitalized terms used in this Grant but not
otherwise defined shall have the same meanings as in the 2004 Stock Incentive Plan, as amended (the “Plan”). 
 2. The
Option. You may, at your discretion and on the terms and conditions set forth herein, purchase all or any part of an aggregate of the shares of Common Stock at the price per share set forth in the Grant Summary (the “Summary”).

 3. Terms of Exercise. 
 (a) Subject to the provisions of Sections 4, 5, 6, and 7 below, as applicable, the Option shall vest and be exercisable at the option exercise price per share (the “Option Price” or “Exercise
Price”) and as to the specified number of shares (the “Vesting Amount”) on and after the dates set forth under Vesting Schedule and on or before the “Expiration Date” as set forth in the Summary. You have no right to
exercise the Option with respect to any installment until such installment vests as provided in the Summary. The Option granted hereunder shall expire and be no longer exercisable as provided in the Plan and this Grant. 
 (b) The Option may be exercised as to all or any portion of the “Options Granted” covered by an installment of the Option that
has vested and that has not yet expired and become unexercisable as provided in the Plan or this Grant (“Vested Installment”). Vested Installments may be exercised, in whole or in part, by giving notice of exercise to AMO’s stock plan
administrator, which notice shall specify the number of Options Granted to be purchased and shall be accompanied by payment in full of the purchase price in cash or: (i) in whole or in part, through the delivery of shares of Common Stock duly
endorsed for transfer to AMO with a Fair Market Value on the date of delivery equal to the aggregate exercise price of the Option or exercised portion thereof; provided, however, that if such shares of Common Stock were issued to you directly
from AMO, such shares must have been owned by you for at least six months; or (ii) through a combination of cash and the consideration provided in the foregoing subparagraph (i). Payment of cash may be by personal check, cashier’s check or
money market draft on your own account payable to the order of AMO or such other means as the Committee (or with respect to an Option granted to an Independent Director, the Board) shall determine. An exercise is effective only upon receipt of both
the written notice and the payment in full of the purchase price. 

 4. Change in Control. Notwithstanding anything to the contrary in this Grant, in the event
of a Change in Control the Option shall, as of the date of such Change in Control, immediately become vested and exercisable with respect to the full number of Options Granted. 
 5. Termination of Employment. This Section 5 shall apply solely to Options granted to Employees. 
 (a) Except as otherwise provided in a written agreement between you and the Company, in the event of termination of your employment with
the Company for Cause, the Option shall become unexercisable as of the date of such termination and you shall thereafter have no further rights to purchase any of the Optioned Shares. 
 (b) Except as otherwise provided in a written agreement between you and the Company, in the event of your termination of employment with
the Company and its subsidiaries for: 
 (i) Any reason other than for Cause, death, Total Disability, Normal Retirement, or
Job Elimination, the Options shall become unexercisable as of the earlier of (A) the date the Vested Installments expire in accordance with the provisions of Section 3(a) above or (B) three calendar months after the date of
termination. 
 (ii) Death or Total Disability, the Option shall vest in its entirety as of your last date of employment and
shall expire and become unexercisable one calendar year after the date of your termination. 
 (iii) Normal Retirement, the
Option shall expire and become unexercisable as of the earlier of (A) the date the Vested Installments expire in accordance with the provisions at Section 3(a) above or (B) three calendar years after the date of termination.

 (iv) Job Elimination, the Option shall vest in its entirety as of your last date of employment and shall expire and become
unexercisable as of the earlier of (A) the date the Vested Installments expire in accordance with the provisions at Section 3(a) above or (B) three calendar months after the date of termination. Notwithstanding the foregoing, if you
meet the requirements for Normal Retirement at the time your employment is terminated for Job Elimination, your Option shall become vested as of the last date of employment, and your Option shall expire and become unexercisable as of the earlier to
occur of (Y) the date the Option expires in accordance with the provisions of Section 3(a) above or (Z)

 
three calendar years after the date of termination. In order to receive the accelerated vesting set forth in this section (iv), you must sign and deliver to
AMO a release and waiver with respect to any and all claims relating to your employment with or termination from the Company in a form acceptable to AMO. 
 (c) In the event your employment terminates for Normal Retirement or for any reason other than for Cause, death, Total Disability or Job Elimination, the Option shall be exercisable by you (or your successor in
interest in the event of your death after your employment terminates) following your termination of employment only to the extent that installments thereof had become exercisable on or prior to the date of such termination and had not expired and
become unexercisable on or prior to such date. 
 (d) In the event that you are prohibited from exercising the Option within
the otherwise specified time period following termination of employment due to a delay with respect to the administration of the Plan, the circumstances of which are beyond your control, the period of time to exercise the Option shall be extended
and be deemed to begin on the date you are permitted to exercise the Option. In the event that you are unable to exercise your Option after your termination of employment because AMO has blocked all trading of Options by all optionees for
administrative or legal purposes, the days covered by the block will not count toward your exercise period. 
 6. Term of
Options Granted to Independent Directors. This Section 6 shall apply solely to Options granted to Independent Directors. 
 (a) Except as otherwise provided in a written agreement between you and the Company, no Option granted to an Independent Director may be
exercised to any extent by anyone after the first to occur of the following events: 
 (i) The expiration of one calendar
year from the date of the Independent Director’s termination of directorship by reason of his or her death or Total Disability; 
 (ii) The expiration of three calendar months from the date of the Independent Director’s termination of directorship for any reason other than such Independent Director’s death or his or her Total
Disability, unless the Independent Director dies within said three calendar month period, in which case the Option shall expire one year from the date of the Independent Director’s death; or 
 (iii) The expiration of 10 years from the date the Option was granted. 
 (b) In the event your service as a Director terminates, the Option shall be exercisable by you (or your successor in interest in the
event of your death 

 
after your service terminates) following your termination of service only to the extent that installments thereof had become exercisable on or prior to the
date of such termination and had not expired and become unexercisable on or prior to such date. 
 7. Term of Options Granted to
Consultants. This Section 7 shall apply solely to Options granted to Consultants. 
 (a) Except as otherwise
provided in a written agreement between you and the Company, no Option granted to a Consultant may be exercised to any extent by anyone after the first to occur of the following events: 
 (i) The expiration of one calendar year from the date of the Consultant’s termination of consultancy by reason of his or her death
or Total Disability; 
 (ii) The expiration of three calendar months from the date of the Consultant’s termination of
consultancy for any reason other than such Consultant’s death or his or her Total Disability, unless the Consultant dies within said three calendar month period, in which case the Option shall expire one calendar year from the date of the
Consultant’s death; or 
 (iii) The expiration of 10 years from the date the Option was granted. 
 (b) In the event your service as a Consultant terminates, the Option shall be exercisable by you (or your successor in interest in the
event of your death after your service terminates) following your termination of service only to the extent that installments thereof had become exercisable on or prior to the date of such termination and had not expired and become unexercisable on
or prior to such date. 
 8. Definitions. As used herein, “calendar month” means 30 days, and “calendar
year” means 365 days. 
 9. Grant Subject to Plan. The grant of the Option evidenced hereby is made pursuant to all of the
provisions of the Plan, and this Grant is intended, and shall be interpreted in a manner to comply therewith. Any provision of this Grant which is inconsistent with Plan shall be superseded by and governed by the Plan. 
 10. Disputes and Disagreements. Any dispute or disagreement which may arise under or as a result of or pursuant to this Grant shall be
determined by the Committee in its sole discretion, and any interpretation by the Committee (or with respect to an Option granted to an Independent Director, the Board in its sole discretion) of the terms of this Grant shall be final, binding and
conclusive. 
  

 11. Notices. All notices or other communications required or permitted hereunder shall be
in writing, and shall be sufficient in all respects only if delivered in person or sent via certified mail or overnight delivery service such as Federal Express, postage prepaid, addressed as follows: 
  

							
		 	 If to the Company:
	  	1700 East St. Andrew Place
		 		  	Santa Ana, California 92705
		 		  	Attention: General Counsel
			
		 	 If to you:
	  	To your address as last set forth
		 		  	in the Company’s employment records.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]